Dr. Mamus is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3830 Bee Ridge Rd
Suite 100
Sarasota, FL 34233Phone+1 941-923-1872Fax+1 941-923-3947
Summary
- Dr. Steven Mamus is an oncologist in Sarasota, FL and is affiliated with multiple hospitals in the area, including Orlando Regional Medical Center, Blake Medical Center, Doctors Hospital of Sarasota, Lakewood Ranch Medical Center, Manatee Memorial Hospital, and Sarasota Memorial Health Care System. He received his medical degree from State University of New York Upstate Medical University and has been in practice 37 years. He specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, platelet disorders, thrombocytopenia, and myelodysplasia.
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 1983 - 1986
Rush University Medical CenterResidency, Internal Medicine, 1980 - 1983
SUNY Upstate Medical UniversityClass of 1980
Certifications & Licensure
FL State Medical License 1986 - 2026
VA State Medical License 2006 - 2008
MN State Medical License 1983 - 1986
IL State Medical License 1982 - 1984- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Best Doctors Southeast Best Doctors, 1995-2015
- Sarasota Magazine: Top Doctors Castle Connolly, 2011-2014
- Top Doctors: Florida Castle Connolly, 2000
Publications & Presentations
PubMed
- 5 citationsA phase II study of pemetrexed in patients with advanced hepatocellular carcinoma.Allen Lee Cohn, J. William Myers, Steven Mamus, Charles Deur, Steven J. Nicol
Investigational New Drugs. 2008-02-28 - 2 citationsBi-clonal disease in patients with chronic lymphocytic leukaemia as detected by analysing IGHV mutation status.Mohammad Reza Sheikholeslami, Wanlong Ma, Jennifer Uyeji, Karl Tornyos, Lawrence A Cone
British Journal of Haematology. 2007-11-01 - 16 citationsPhase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic...Francis J. Giles, Eric J. Feldman, Gail J. Roboz, Richard A. Larson, Steven W. Mamus
Leukemia Research. 2003-12-01
Press Mentions
Prominent Oncologist to Discuss Advantages of Oxford BioDynamics’ EpiSwitch CiRT at the 2022 Liquid Biopsy Virtual SummitNovember 21st, 2022- OBD EpiSwitch® CiRT Well Received at ASCO 2022June 14th, 2022
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
